Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
20
RNAC Quote, Financials, Valuation and Earnings
Last price:
$6.79
Seasonality move
:
0.08%
Day range:
$6.41 - $6.83
52-week range:
$5.98 - $20.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
75.41x
P/B ratio:
568.21x
Volume:
111.1K
Avg. volume:
189.5K
1-year change:
-63.4%
Market cap:
$175.8M
Revenue:
$38.9M
EPS (TTM):
-$2.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
$177.6K | -$0.63 | -90.89% | -15.55% | $35.29 |
|
ACLX
Arcellx, Inc.
|
$10.3M | -$1.03 | 0.14% | -19.95% | $112.35 |
|
CABA
Cabaletta Bio, Inc.
|
-- | -$0.46 | -- | -27.29% | $14.13 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
RGEN
Repligen Corp.
|
$181.7M | $0.41 | 15.06% | 289.59% | $189.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
$6.76 | $35.29 | $175.8M | -- | $0.00 | 0% | 75.41x |
|
ACLX
Arcellx, Inc.
|
$66.07 | $112.35 | $3.8B | -- | $0.00 | 0% | 102.31x |
|
CABA
Cabaletta Bio, Inc.
|
$2.20 | $14.13 | $211.3M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
RGEN
Repligen Corp.
|
$165.66 | $189.22 | $9.3B | 6,420.93x | $0.00 | 0% | 13.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
-54.23% | 1.511 | 4.74% | 10.44x |
|
ACLX
Arcellx, Inc.
|
10.52% | 0.952 | 1.09% | 3.90x |
|
CABA
Cabaletta Bio, Inc.
|
15.6% | 6.169 | 11.44% | 3.50x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
RGEN
Repligen Corp.
|
24.85% | 1.126 | 9.16% | 6.86x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
$452K | -$21.1M | -- | -- | -4660.62% | -$20.1M |
|
ACLX
Arcellx, Inc.
|
$3.1M | -$61.8M | -44.21% | -49.8% | -1248.25% | -$49.5M |
|
CABA
Cabaletta Bio, Inc.
|
-$345K | -$46.6M | -90.44% | -103.46% | -- | -$34.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
RGEN
Repligen Corp.
|
$90.6M | $14.8M | 0.06% | 0.09% | 7.83% | $42.7M |
Cartesian Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RNAC or ACLX?
Arcellx, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of -1127.12%. Cartesian Therapeutics, Inc.'s return on equity of -- beat Arcellx, Inc.'s return on equity of -49.8%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M ACLXArcellx, Inc.62.76% -$0.99 $492.6M -
What do Analysts Say About RNAC or ACLX?
Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 421.98%. On the other hand Arcellx, Inc. has an analysts' consensus of $112.35 which suggests that it could grow by 71.51%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Arcellx, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than Arcellx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 ACLXArcellx, Inc.15 2 0 -
Is RNAC or ACLX More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Arcellx, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RNAC or ACLX?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcellx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Arcellx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or ACLX?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than Arcellx, Inc. quarterly revenues of $4.9M. Cartesian Therapeutics, Inc.'s net income of -$35.9M is higher than Arcellx, Inc.'s net income of -$55.8M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcellx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 75.41x versus 102.31x for Arcellx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.75.41x -- $452K -$35.9M ACLXArcellx, Inc.102.31x -- $4.9M -$55.8M
-
Which has Higher Returns RNAC or CABA?
Cabaletta Bio, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Cabaletta Bio, Inc.'s return on equity of -103.46%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M CABACabaletta Bio, Inc.-- -$0.44 $165.2M -
What do Analysts Say About RNAC or CABA?
Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 421.98%. On the other hand Cabaletta Bio, Inc. has an analysts' consensus of $14.13 which suggests that it could grow by 547.94%. Given that Cabaletta Bio, Inc. has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Cartesian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 CABACabaletta Bio, Inc.7 2 0 -
Is RNAC or CABA More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Cabaletta Bio, Inc. has a beta of 3.171, suggesting its more volatile than the S&P 500 by 217.108%.
-
Which is a Better Dividend Stock RNAC or CABA?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cabaletta Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Cabaletta Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or CABA?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Cabaletta Bio, Inc. quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is higher than Cabaletta Bio, Inc.'s net income of -$44.9M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Cabaletta Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 75.41x versus -- for Cabaletta Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.75.41x -- $452K -$35.9M CABACabaletta Bio, Inc.-- -- -- -$44.9M
-
Which has Higher Returns RNAC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of -255.85%. Cartesian Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About RNAC or NBY?
Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 421.98%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Cartesian Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is RNAC or NBY More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock RNAC or NBY?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or NBY?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 75.41x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.75.41x -- $452K -$35.9M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns RNAC or PTN?
Palatin Technologies has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About RNAC or PTN?
Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 421.98%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Cartesian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 PTNPalatin Technologies0 0 0 -
Is RNAC or PTN More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock RNAC or PTN?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or PTN?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Palatin Technologies quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is higher than Palatin Technologies's net income of --. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 75.41x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.75.41x -- $452K -$35.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns RNAC or RGEN?
Repligen Corp. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of 7.9%. Cartesian Therapeutics, Inc.'s return on equity of -- beat Repligen Corp.'s return on equity of 0.09%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M RGENRepligen Corp.47.99% $0.26 $2.8B -
What do Analysts Say About RNAC or RGEN?
Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 421.98%. On the other hand Repligen Corp. has an analysts' consensus of $189.22 which suggests that it could grow by 14.22%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Repligen Corp., analysts believe Cartesian Therapeutics, Inc. is more attractive than Repligen Corp..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 RGENRepligen Corp.14 5 0 -
Is RNAC or RGEN More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.028%.
-
Which is a Better Dividend Stock RNAC or RGEN?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or RGEN?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than Repligen Corp. quarterly revenues of $188.8M. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than Repligen Corp.'s net income of $14.9M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Repligen Corp.'s PE ratio is 6,420.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 75.41x versus 13.20x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.75.41x -- $452K -$35.9M RGENRepligen Corp.13.20x 6,420.93x $188.8M $14.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
